| 摘要 |
The application describes a vaccine that comprises (A) cells, cell lysates, or cell derivatives of Staphylococcus aureus which carry an antigen that i) comprises â-linked hexosamine, ii) contains no O-acetyl groups detectable by nuclear magnetic resonance spectroscopy, and iii) specifically binds antibodies to Staphylococcus aureus Type 336 deposited under ATCC 55804, (B) cells, cell lysates or cell derivatives of Staphylococcus aureus which carry Type 5 antigen and/or cells, cell lysates, or cell derivatives of Staphylococcus aureus which carry Type 8 antigen and (C) a pharmaceutically acceptable carrier. A use of the vaccine is described for the preparation of an agent for the treatment of a subject that has or is at risk of developing an S. aureus infection.
|
